Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
A key deadline for the incoming administration is Feb. 1, 2025, by which Medicare must select up to 15 high-cost drugs to negotiate prices on. While the Biden administration may select these drugs ...
The FDA has implemented new rules for TV and radio drug ads, effective Nov. 20, aimed at making the advertisements more clear and direct in explaining medication risks and side effects, The Sun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback